We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
Turnover
16.03%
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
5.4
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
601
Keros Therapeutics
KROS
$220M
| $8.73M | 0.02% |
654,030
-570,109
| -47% | -$7.7M |
2024 Q4
2 quarters
|
|
602
Adient
ADNT
$1.4B
| $8.72M | 0.02% |
448,022
-76,319
| -15% | -$1.13M |
2018 Q3
27 quarters
|
|
603
Alibaba
BABA
$276B
| $8.67M | 0.02% |
76,415
-23,838
| -24% | -$2.82M |
2014 Q3
43 quarters
|
|
604
Royal Bank of Canada
RY
$272B
| $8.59M | 0.02% |
65,264
-1,071
| -2% | -$131K |
2020 Q2
20 quarters
|
|
605
Scholar Rock
SRRK
$4.95B
| $8.54M | 0.02% |
241,000
+238,791
| +10,810% | +$7.5M |
2025 Q1
1 quarter
|
|
606
Clear Secure
YOU
$4.63B
| $8.52M | 0.02% |
306,924
-257,104
| -46% | -$6.55M |
2022 Q4
10 quarters
|
|
607
Universal Technical Institute
UTI
$1.13B
| $8.52M | 0.02% |
251,269
+1,074
| +0.4% | +$33.7K |
2023 Q4
6 quarters
|
|
608
WESCO International
WCC
$16.9B
| $8.49M | 0.02% |
45,837
-6,226
| -12% | -$1.03M |
2013 Q2
48 quarters
|
|
609
The Gap Inc
GAP
$8.24B
| $8.44M | 0.02% |
386,897
-1,427,050
| -79% | -$31.9M |
2013 Q2
48 quarters
|
|
610
Green Plains
GPRE
$1B
| $8.41M | 0.02% |
1,394,570
-432,185
| -24% | -$1.91M |
2025 Q1
1 quarter
|
|
611
The RMR Group
RMR
$319M
| $8.36M | 0.02% |
511,316
-27,784
| -5% | -$426K |
2019 Q3
23 quarters
|
|
612
Shell
SHEL
$295B
| $8.34M | 0.02% |
118,448
-2,668
| -2% | -$179K |
2022 Q1
13 quarters
|
|
613
Alignment Healthcare
ALHC
$1.69B
| $8.32M | 0.02% |
594,489
+13,206
| +2% | +$213K |
2024 Q3
3 quarters
|
|
614
Atmus Filtration Technologies
ATMU
$3.59B
| $8.32M | 0.02% |
228,507
-120,662
| -35% | -$4.3M |
2023 Q4
6 quarters
|
|
615
Takeda Pharmaceutical
TAK
$62.1B
| $8.26M | 0.02% |
534,027
-7,892
| -1% | -$117K |
2022 Q4
10 quarters
|
|
616
Unilever
UL
$139B
| $8.24M | 0.02% |
119,812
+24,680
| +26% | +$1.73M |
2018 Q1
29 quarters
|
|
617
Brixmor Property Group
BRX
$8.42B
| $8.21M | 0.02% |
315,459
-2,842
| -0.9% | -$72.2K |
2016 Q1
37 quarters
|
|
618
Telefônica Brasil
VIV
$19.6B
| $8.14M | 0.02% |
713,677
+100,762
| +16% | +$990K |
2018 Q1
29 quarters
|
|
619
C3.ai
AI
$1.96B
| $7.98M | 0.02% |
324,592
-65,263
| -17% | -$1.49M |
2025 Q1
1 quarter
|
|
620
Nucor
NUE
$57.8B
| $7.86M | 0.01% |
60,709
-14,475
| -19% | -$1.69M |
2013 Q2
48 quarters
|
|
621
Travere Therapeutics
TVTX
$4.98B
| $7.81M | 0.01% |
527,538
-145,110
| -22% | -$2.41M |
2024 Q2
4 quarters
|
|
622
DELISTED
Taylor Morrison
TMHC
| $7.77M | 0.01% |
126,522
-17,246
| -12% | -$1M |
2019 Q3
23 quarters
|
|
623
Ecolab
ECL
$81.5B
| $7.76M | 0.01% |
28,809
-36,127
| -56% | -$9.18M |
2013 Q2
48 quarters
|
|
624
Bumble
BMBL
$783M
| $7.73M | 0.01% |
1,173,055
+428,559
| +58% | +$2.16M |
2025 Q1
1 quarter
|
|
625
ON Semiconductor
ON
$28.7B
| $7.71M | 0.01% |
147,102
-332,376
| -69% | -$14.4M |
2013 Q4
46 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.